RT @EBRheum: #ACR19 Abst#2877: Open Label Extension of a Phase 2 for risankizumab (IL23i) for PsA Effect seems to stick around and favorab…
Tweet Content
#ACR19 Abst#2877: Open Label Extension of a Phase 2 for risankizumab (IL23i) for PsA
Effect seems to stick around and favorable safety profile
@RheumNow https://t.co/pFn0q61exs
Show on Archive Page
On
Display in Search Results
On